Double Blind Study Reveals Los Angeles-Based, EZC Pak’s, as an Effective Alternative to Antibiotics for Treating Upper Respiratory Infections

Screenshot 2023 05 11 at 4.42.37 PM

A groundbreaking double-blind study announced on May 3rd by Los Angeles-based EZC Pak has uncovered a promising alternative to antibiotics for treating upper respiratory infections (URIs). This NIH-registered clinical trial spanned nine months, enrolling 360 patients from across the United States. Findings reveal that participants who took EZC Pak’s immune support pack recovered 1.39 days faster (p=0.017), experienced a 17.43% reduction in symptom severity (p=0.029), and had 2.9 times greater patient satisfaction (p=0.012) compared to those taking a placebo.

These results substantiate EZC Pak‘s immune support formula and five-day tapered system as an effective, evidence-based solution to antibiotic misuse in managing colds, flus, and other URIs. This is especially significant given the urgent global public health threat posed by antibiotic resistance, which the CDC estimates to be associated with 1.27 million deaths each year.

The vast majority of URIs, approximately 80%, are caused by viruses. Yet, despite the absence of bacterial infections, antibiotics continue to be prescribed excessively. This misuse has driven the medical community to seek alternative treatments for URIs, such as EZC Pak’s five-day dose pack of echinacea, zinc, and vitamin C, which has demonstrated its effectiveness in reducing both the duration and severity of symptoms.

Screenshot 2023 05 11 at 4.42.56 PM

EZC Pak, a clinically tested, all-natural rapid immune support solution, contains professional-strength doses of echinacea, zinc, and vitamin C. This physician-formulated product enables patients to organically combat viral respiratory infections without overusing antibiotics or needing a prescription. In the post-pandemic era, EZC Pak emerged as a highly accessible, clinically proven immunity boost for individuals seeking relief from URIs and other common viruses.

Dr. Sarath Malepati, a general surgery specialist in Los Angeles and a graduate of Wake Forest University School of Medicine, founded EZC Pak. His motivation stemmed from the increasing number of patients suffering from complex, drug-resistant infections such as MRSA (methicillin-resistant Staphylococcus aureus) and C.diff (Clostridium difficile). As antibiotic treatment became increasingly ineffective, he sought alternative solutions for addressing antibiotic overuse.

Dr. Malepati’s research led him to a CDC pamphlet advocating echinacea for URI treatment. Further investigation revealed that Echinacea purpurea and zinc acetate had evidence supporting their use, while vitamin C had long been popular among patients. This insight was the catalyst to Dr. Malepati’s development of EZC Pak’s potent blend of echinacea, zinc, and vitamin C. EZC Pak’s professional strength dose of echinacea, zinc, and vitamin C and proven over-the-counter accessibility is among the many factors distinguishing it from its competitors.

Screenshot 2023 05 11 at 4.43.03 PM

With robust clinical data supporting its efficacy, in addition to the recent ground-breaking double-blind study, EZC Pak stands as the solitary over-the-counter, physician-endorsed solution available at pharmacies, drug stores, and online platforms. It can be conveniently purchased without a prescription at CVS, Rite Aid, select U.S. grocery stores, and online retailers such as Amazon, Walmart, and the company’s website. This accessibility enables individuals to recover more quickly without resorting to antibiotics or prescription drugs.

As antibiotic resistance continues to pose a significant global public health threat, Los Angeles-based EZC Pak offers a promising, organic solution to fight off viral respiratory infections without overusing antibiotics or requiring a prescription. Its innovative, physician-formulated approach not only addresses the critical issue of antibiotic overuse but also empowers patients and doctors alike with a safe, effective, and convenient alternative to treat upper respiratory infections.

Advertising disclosure: We may receive compensation for some of the links in our stories. Thank you for supporting LA Weekly and our advertisers.